The average med spa runs a gross margin of roughly 55–70% and a net profit margin of 20–25% — but those two numbers get mashed together so often that most owners can’t tell you which one they’re actually earning. I work with med spa owners every week, and the question “is my margin normal?” almost never has a clean answer online because nobody publishes the service-line breakdown. So here it is: the benchmark table, the full P&L, and where the margin actually leaks.
The headline benchmarks — and what “margin” means at each line
Three different numbers get called “profit margin,” and they live at three different lines of your P&L:
- Gross margin — revenue minus direct product cost (vials, syringes, tips, IV bags). Healthy med spas run 55–70% blended.
- Contribution margin — gross margin minus the variable cost of delivering the treatment, mainly provider compensation and room supplies. This is the number that actually tells you whether a service line is worth growing. Typically 35–55% by line (est.).
- Net margin (or EBITDA) — what’s left after rent, admin, marketing, software, insurance, and your medical director. Industry sources tracking AmSpa’s State of the Industry data consistently put healthy single-location spas at 20–25% net, with well-run operations reaching 27–30% EBITDA and top performers touching 30–40%. Boulevard’s 2025 industry analysis pegs average med spa revenue near $2 million with that same 20–25% net range.
If someone quotes you “70% margins in aesthetics,” they’re talking gross margin on injectables product cost — not what hits your bank account. Keep the three lines separate and every benchmark below will make sense.
Profit margin by med spa service line
This is the table nobody assembles. Gross margin is revenue minus consumables; contribution margin also subtracts provider comp and treatment-room variable costs. All contribution figures are my estimates (est.) built from published consumable costs and typical commission structures — your numbers will move with your comp model and local pricing.
| Service line | Gross margin | Contribution margin (est.) | Notes |
|---|---|---|---|
| Neurotoxins (Botox, Dysport, etc.) | 60–75% | 35–45% | AbbVie’s published wholesale price is $656 per 100-unit vial; most spas pay $500–600 through distributors and charge $10–16/unit. Injector commission eats the gap. |
| Dermal fillers | 50–65% | 30–45% | Syringe cost $250–400, retail $650–900. Better per-appointment economics than tox because one syringe = one sale. |
| Laser hair removal | 75–90% | 50–65% | Almost no consumables — under $5 per session in power and wear per industry equipment analyses — but the device costs $30K–120K up front. Margins are excellent once the laser is paid off. |
| Skin treatments / facials / peels | 60–75% | 30–45% | Low product cost, but esthetician time per dollar of revenue is high. Great for retention, mediocre for profit density. |
| GLP-1 / medical weight loss | 70–85% | 50–65% | Compounded semaglutide has cost spas $40–120/month per patient against $250–400/month program pricing. Regulatory risk is the asterisk — the FDA moved in 2026 to pull semaglutide and tirzepatide from the 503B compounding list, so model brand-drug economics too. |
| IV therapy | 50–65% | 25–35% | Per the American IV Association, roughly 40% of the price goes to ingredients and 25% to staff time; the industry averages around 35% margins. Chair time is the constraint. |
| Memberships | n/a | 60%+ on the recurring fee (est.) | The margin isn’t in the membership itself — it’s in the visit frequency and pre-committed revenue smoothing your utilization. |
The pattern worth noticing: the services with the best contribution margins (laser, GLP-1, memberships) are exactly the ones most spas under-market, while everyone fights over tox patients at discounted per-unit prices.
The full benchmark P&L: a $1M med spa, line by line
Here’s what a healthy $1M single-location spa looks like (est., blended service mix weighted toward injectables):
| Line item | % of revenue | Dollars |
|---|---|---|
| Revenue | 100% | $1,000,000 |
| COGS (vials, syringes, consumables, retail product) | 25–32% | $250,000–320,000 |
| Gross profit | 68–75% | $680,000–750,000 |
| Provider compensation (injectors, estheticians, RNs) | 20–28% | $200,000–280,000 |
| Rent and facilities | 6–10% | $60,000–100,000 |
| Marketing | 8–12% | $80,000–120,000 |
| Admin, front desk, software, insurance, medical director | 10–14% | $100,000–140,000 |
| Net operating profit | 18–26% | $180,000–260,000 |
Two notes on that marketing line. AmSpa’s State of the Industry reporting has put the industry average around 7% of revenue, with the observed range running 2–15%. I benchmark growth-mode spas at 8–12% because at 7% most sub-$1.5M spas can’t buy enough demand to fill provider capacity — and empty injector hours are the most expensive line item that never appears on a P&L. If you want to see how I structure that spend, my med spa marketing services page breaks down where those dollars should go by revenue stage.
Why injectables look high-margin but aren’t
Tox is the service everyone assumes prints money. The gross math looks great: pay ~$6 per unit, charge $12–14. But three things erode it before it reaches net profit:
- Waste and reconstitution loss. A reconstituted vial has a limited usable window. If your booking density doesn’t consume vials fully, you’re throwing away 5–15% of product (est.). At $600 a vial, sloppy scheduling is a silent four-figure monthly loss.
- Injector compensation. Whether you pay hourly-plus-commission or straight percentage, 20–30% of injectable revenue typically goes to the person holding the syringe. That’s the single biggest gap between gross and contribution margin.
- Room time economics. A 50-unit tox appointment and a 2-syringe filler appointment occupy similar room time, but the filler visit generates roughly double the contribution dollars. Per-hour, tox is often your weakest injectable.
Run your own numbers in my free Botox per-unit margin calculator — it accounts for vial cost, waste rate, and injector comp, and most owners are surprised where their true per-unit profit lands.
The 5 fastest margin killers, ranked
- No-shows and late cancellations. A 15% no-show rate on a $250 average ticket destroys more profit than any supplier price increase. My no-show cost calculator puts a real annual dollar figure on yours — for most $1M spas it’s $40K–90K (est.).
- Discounting tox to compete on price. Dropping from $13 to $10 per unit cuts your contribution margin on that service by roughly a third while attracting the least loyal patient segment.
- Missed calls during treatment hours. Front desks in treatment-heavy spas miss 25–40% of inbound calls (est.), and each missed new-patient call is a lost lifetime value, not a lost appointment. The missed-call calculator shows the math.
- Provider under-utilization. An injector at 60% booked capacity costs the same as one at 90%. Utilization is a marketing and rebooking problem wearing a staffing costume.
- Untracked product waste and shrinkage. Spas that don’t reconcile units purchased against units charged routinely find 5–10% leakage (est.).
Margin vs. scale: $500K to $3M
Net margin is not flat across revenue sizes — it follows a U-curve in reverse:
- $500K revenue: 10–18% net (est.). Fixed costs — rent, medical director, software, minimum viable staffing — consume a huge share. Many owners here pay themselves out of what should be profit.
- $1M–1.5M: 20–27% net. Fixed costs get absorbed, providers approach full utilization. Industry analyses of AmSpa data suggest a well-run spa around $1.5M should produce roughly 27% EBITDA. This is the sweet spot for a single location.
- $2M–3M: 22–30% net (est.), but only with management discipline. You’re now adding a second layer — practice manager, more marketing, possibly a second location — and margin dips before it recovers. Spas that scale service mix toward laser, weight-loss programs, and memberships hold margin better than tox-dependent ones.
Compliance risk also scales with revenue — advertising claims that fly under the radar at $500K attract board scrutiny at $3M. My med spa advertising compliance guide covers what changes as you grow.
The 90-day margin improvement plan
Days 1–30: Measure. Split your P&L by service line. Reconcile product purchased vs. product billed. Pull your no-show rate, missed-call rate, and provider utilization. You cannot fix a margin you haven’t located.
Days 31–60: Plug the leaks. Add card-on-file deposits for high no-show services. Set up missed-call text-back. Tighten vial scheduling so tox days consume full vials. Renegotiate with your distributor if you’re buying more than 10 vials a month — volume pricing moves fast.
Days 61–90: Shift the mix. Push marketing weight toward your highest contribution-margin lines — laser packages, weight-loss programs (model both compounded and brand-drug economics with my GLP-1 program profit calculator), and memberships. Instagram remains the cheapest demand channel for these — my med spa Instagram marketing guide shows the content formats that fill high-margin services specifically.
Done in sequence, a 3–5 point net margin improvement inside a quarter is a realistic target for most spas under $2M (est.) — that’s $30K–50K a year on a $1M practice, without a single new patient. If you want to see how margin translates into what you actually take home, I break that down in how much med spa owners make.
Want a second set of eyes on this for your clinic? Book a free strategy call or call/text me at +91 97297 12388.
Frequently asked questions
Is a med spa profitable?
Yes — a well-run med spa is one of the more profitable small healthcare-adjacent businesses. Industry data referencing AmSpa’s State of the Industry reporting puts healthy net margins at 20–25%, with top performers reaching 30–40%. The failure mode isn’t the business model; it’s under-utilized providers, unmanaged product waste, and marketing spend too low to fill capacity.
What is a good profit margin for Botox?
A good gross margin on tox is 60–75%: product cost around $5–6.50 per unit (based on $500–656 per 100-unit vial) against retail of $10–16 per unit. After injector compensation and waste, a realistic contribution margin is 35–45% (est.). If you’re below 30%, look at your comp structure, waste rate, or per-unit price before assuming volume will fix it.
What is the average med spa profit margin?
Gross margin averages 55–70% blended across services; net profit margin averages 20–25% for healthy operations, per industry benchmarks built on AmSpa data. Spas around $1.5M in revenue with disciplined operations can reach roughly 27% EBITDA.
Which med spa service has the highest profit margin?
Laser hair removal has the highest gross margin (75–90%) once equipment is paid off, because per-session consumable cost is negligible. GLP-1 weight-loss programs have run 70–85% gross margins on compounded medication, though FDA action on compounded semaglutide means those economics are shifting toward brand-drug pricing. On a contribution basis, laser and weight-loss programs both beat injectables.
How much should a med spa spend on marketing?
AmSpa’s reporting has put the industry average near 7% of revenue, with a 2–15% observed range. I recommend 8–12% for spas in growth mode and 10–15% for new spas building a patient base — below that, most spas can’t generate enough demand to keep providers fully booked, and idle provider hours cost more than the marketing would have.
Why is my med spa revenue growing but profit shrinking?
Usually one of three things: your service mix is drifting toward low contribution-margin services (basic facials, discounted tox), your provider comp scales with revenue while utilization stays flat, or you added fixed costs (staff, space, devices) ahead of the revenue to absorb them. Split your P&L by service line and the culprit is almost always visible within an hour.
